Related Experiment Videos
Current Therapy for Mesothelioma.
1Division of Thoracic Surgery, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Summary
Diffuse malignant pleural mesotheliomas (DMPMs) are aggressive cancers. An aggressive trimodality approach shows promise, with a 40% five-year survival rate for specific patients, highlighting the need for better treatments.
Area of Science:
- Oncology
- Thoracic Surgery
- Medical Oncology
Background:
- Diffuse malignant pleural mesotheliomas (DMPMs) represent a significant and increasing oncological challenge.
- Current standard management strategies offer limited efficacy for DMPMs.
- Aggressive treatment approaches are under investigation due to the high lethality of DMPMs.
Purpose of the Study:
- To revise the literature on DMPM management.
- To present outcomes data for 120 patients treated with an aggressive trimodality approach.
- To identify key prognostic factors for DMPM survival.
Main Methods:
- Literature review on DMPM management.
- Retrospective analysis of outcomes for 120 patients.
- Treatment involved an aggressive trimodality approach including extrapleural pneumonectomy, followed by chemoradiation.
Main Results:
- The aggressive trimodality approach demonstrated low mortality and acceptable morbidity.
- A five-year survival rate approaching 40% was observed in patients with epithelial histology and negative nodal status.
- Nodal status and histologic subtype emerged as critical predictors of survival in early-stage DMPM.
Conclusions:
- Nodal status and histologic subtype are major prognostic indicators for early DMPM.
- A standardized staging system is needed to compare treatment outcomes across institutions.
- Further development of effective management interventions for DMPM is essential.